Camila Motta Venchiarutti Moniz

Camila Motta Venchiarutti Moniz

Auto-generated profile, based on publicly available information

Camila Motta Venchiarutti Moniz

Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Hypertension
Verified
Journal Article
Closed access
PDF file
DFDiego Faria
Diego Faria
RMRenata Moll-Bernardes
Renata Moll-Bernardes
LTLaura Testa
Laura Testa
CMCamila M.V. Moniz
Camila M.V. Moniz
ERErika C. Rodrigues
Erika C. Rodrigues
ASAllan R.K. Sales
Allan R.K. Sales
Background: COVID-19 has become a dramatic health problem during this century. In addition to high mortality rate, COVID-19 survivors are at increased risk for cardiovascular diseases 1-year after infection. Explanations for these manifestations are still unclear but can involve a constellation of biological alterations. We hypothesized that COVID-19 survivors compared with controls exhibit sympathetic overdrive, vascular dysfunction, cardiac morpho-functional changes, impaired exercise capacity, and increased oxidative stress. Methods: Nineteen severe COVID-19 survivors and 19 well-matched controls completed the study. Muscle sympathetic nerve activity (microneurography), brachial artery flow-mediated dilation and blood flow (Doppler-Ultrasound), carotid-femoral pulse wave velocity (Complior), cardiac morpho-functional parameters (echocardiography), peak oxygen uptake (cardiopulmonary exercise testing), and oxidative stress were measured ~3 months after hospital discharge. Complementary experiments were conducted on human umbilical vein endothelial cells cultured with plasma samples from subjects. Results: Muscle sympathetic nerve activity and carotid-femoral pulse wave velocity were greater and brachial artery flow-mediated dilation, brachial artery blood flow, E/e′ ratio, and peak oxygen uptake were lower in COVID-19 survivors than in controls. COVID-19 survivors had lower circulating antioxidant markers compared with controls, but there were no differences in plasma-treated human umbilical vein endothelial cells nitric oxide production and reactive oxygen species bioactivity. Diminished peak oxygen uptake was associated with sympathetic overdrive, vascular dysfunction, and reduced diastolic function in COVID-19 survivors. Conclusions: Our study revealed that COVID-19 survivors have sympathetic overactivation, vascular dysfunction, cardiac morpho-functional changes, and reduced exercise capacity. These findings indicate the need for further investigation to determine whether these manifestations are persistent longer-term and their impact on the cardiovascular health of COVID-19 survivors.

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
NGNader Marta Guilherme
Nader Marta Guilherme
RBRenata Colombo Bonadio
Renata Colombo Bonadio
OSOdeli Nicole Encinas Sejas
Odeli Nicole Encinas Sejas
GWGabriel Watarai
Gabriel Watarai
MMMaria Cecilia Mathias Machado
Maria Cecilia Mathias Machado
PHPaulo M. Hoff
Paulo M. Hoff
PURPOSE: Patients with cancer are at increased risk for unfavorable outcomes from COVID-19. Knowledge about the outcome determinants of severe acute respiratory syndrome coronavirus 2 infection in this population is essential for risk stratification and definition of appropriate management. Our objective was to evaluate prognostic factors for all-cause mortality in patients diagnosed with both cancer and COVID-19. METHODS: All consecutive patients with cancer hospitalized at our institution with COVID-19 were included. Electronic medical records were reviewed for clinical and laboratory characteristics potentially associated with outcomes. RESULTS: Five hundred seventy-six consecutive patients with cancer and COVID-19 were included in the present study. An overall in-hospital mortality rate of 49.3% was demonstrated. Clinical factors associated with increased risk of death because of COVID-19 were age over 65 years, Eastern Cooperative Oncology Group performance status > 0 zero, best supportive care, primary lung cancer, and the presence of lung metastases. Laboratory findings associated with a higher risk of unfavorable outcomes were neutrophilia, lymphopenia, and elevated levels of D-dimer, creatinine, C-reactive protein, or AST. CONCLUSION: A high mortality rate in patients with cancer who were diagnosed with COVID-19 was demonstrated in the present study, emphasizing the need for close surveillance in this group of patients, especially in those with unfavorable prognostic characteristics.

15 October 2020 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
LKLucas Tokio Kawahara
Lucas Tokio Kawahara
ICIsabela Bispo Santos da Silva Costa
Isabela Bispo Santos da Silva Costa
CBCecília Chie Sakaguchi Barros
Cecília Chie Sakaguchi Barros
GAGabriel Coelho de Almeida
Gabriel Coelho de Almeida
CBCristina Salvadori Bittar
Cristina Salvadori Bittar
PHPaulo M. Hoff
Paulo M. Hoff
Resumo O desafio imposto ao sistema de saúde pela pandemia da COVID-19 faz com que haja uma necessidade de readequações de rotinas e serviços de saúde, com os objetivos de controlar a disseminação do vírus e preservar a saúde. Torna-se ainda mais importante o manejo seguro e correto dos pacientes dos grupos de risco, como os pacientes idosos, os portadores de doenças cardiovasculares e os pacientes com câncer. Dessa forma, a cardio-oncologia ganha novo dimensionamento, no intuito de se adequar [...] Resumo O desafio imposto ao sistema de saúde pela pandemia da COVID-19 faz com que haja uma necessidade de readequações de rotinas e serviços de saúde, com os objetivos de controlar a disseminação do vírus e preservar a saúde. Torna-se ainda mais importante o manejo seguro e correto dos pacientes dos grupos de risco, como os pacientes idosos, os portadores de doenças cardiovasculares e os pacientes com câncer. Dessa forma, a cardio-oncologia ganha novo dimensionamento, no intuito de se adequar

1 January 2020 in Clinics
Verified
Journal Article
Open access
ACAndre Chen
Andre Chen
CMCamila Motta Venchiarutti Moniz
Camila Motta Venchiarutti Moniz
URUlysses Ribeiro-Júnior
Ulysses Ribeiro-Júnior
MEMaria Del Pilar Estevez-Diz
Maria Del Pilar Estevez-Diz
JSJoão Victor Salvajoli
João Victor Salvajoli
PHPaulo Marcelo Gehm Hoff
Paulo Marcelo Gehm Hoff

1 January 2023 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
PDF file
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
ACAmir Zeide Charruf
Amir Zeide Charruf
Carolina VictorCarolina Victor
Carolina Victor
JGJoão Vitor Antunes Marques Gregorio
João Vitor Antunes Marques Gregorio
ADAndre Roncon Dias
Andre Roncon Dias
BACKGROUND: Peritoneal carcinomatosis in gastric cancer is considered a fatal disease, without expectation of definitive cure. As systemic chemotherapy is not sufficient to contain the disease, a multimodal approach associating intraperitoneal chemotherapy with surgery may represent an alternative for these cases. AIMS: The aim of this study was to investigate the role of intraperitoneal chemotherapy in stage IV gastric cancer patients with peritoneal metastasis. METHODS: This study is a single institutional single-arm prospective clinical trial phase II (NCT05541146). Patients with the following inclusion criteria undergo implantation of a peritoneal catheter for intraperitoneal chemotherapy: Stage IV gastric adenocarcinoma; age 18–75 years; Peritoneal carcinomatosis with peritoneal cancer index<12; Eastern Cooperative Oncology Group 0/1; good clinical status; and lab exams within normal limits. The study protocol consists of four cycles of intraperitoneal chemotherapy with paclitaxel associated with systemic chemotherapy. After treatment, patients with peritoneal response assessed by staging laparoscopy undergo conversion gastrectomy. RESULTS: The primary outcome is the rate of complete peritoneal response. Progression-free and overall survivals are other outcomes evaluated. The study started in July 2022, and patients will be screened for inclusion until 30 are enrolled. CONCLUSIONS: Therapies for advanced gastric cancer patients have been evaluated in clinical trials but without success in patients with peritoneal metastasis. The treatment proposed in this trial can be promising, with easy catheter implantation and ambulatory intraperitoneal chemotherapy regime. Verifying the efficacy and safety of paclitaxel with systemic chemotherapy is an important progress that this study intends to investigate.

1 January 2026 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
VCVinicius Humberto Bandeira Cereser
Vinicius Humberto Bandeira Cereser
CMCamila Motta Venchiarutti Moniz
Camila Motta Venchiarutti Moniz
GSGuilherme Suarez-Kurtz
Guilherme Suarez-Kurtz
MEMaria Del Pilar Estevez-Diz
Maria Del Pilar Estevez-Diz
SUMMARY OBJECTIVE: The aim of this study was to determine the frequency of UGT1A1 and DPYD polymorphisms among Brazilian patients with gastrointestinal cancer. METHODS: UGT1A1 and DPYD polymorphisms were selected due to their importance in the metabolism of fluoropyrimidines and irinotecan, and the existence of available clinical guidelines for dosing recommendations based on genetic testing. Polymorphism rs3918290, rs67376798, rs56038477, rs55886062, rs115232898, and rs887829 were investigated in 100 patients. Allelic discrimination was performed using the TaqMan Assay. Minor allele frequencies were calculated, and metabolic phenotypes were inferred based on the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group guidelines. RESULTS: For DPYD, rs56038477 (n=100) showed a minor allele frequency of 1.50% (CI 0.51–4.32), rs115232898 (n=49) had a minor allele frequency of 1.02% (CI 0.18–5.56), and rs3918290 (n=100) had a minor allele frequency of 0.50% (CI 0.09–2.78). No variants were observed in rs67376798 (n=100) or rs55886062 (n=44). A total of 4% of patients received a Clinical Pharmacogenetics Implementation Consortium DPYD activity score (AS) of less than 2.0, with 3% of 1.5 AS and 1% of 0.5 AS. For UGT1A1, rs887829 (n=100) revealed a minor allele frequency of 37.5% (CI 31.09–44.39) and 16% of patients with Dutch Pharmacogenetics Working Group poor metabolizer phenotype. CONCLUSION: The presence of DPYD and UGT1A1 variants is considerable among Brazilian gastrointestinal cancer patients, reinforcing the promising use of pre-therapeutic genetic tests for irinotecan and fluoropyrimidines to avoid severe toxicities related to treatment. Genetic panels for these variants must be continuously updated and adapted for population-specific characteristics.